# Postbariatric Hypoglycemia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/postbariatric-hypoglycemia

> 2 upcoming FDA catalysts in postbariatric Hypoglycemia: mizagliflozin (VOGX) on October 2027 (primary completion); mizagliflozin (VOGX) on Oct 2027 to Jan 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 18, 2026 | [Mbx 1416 (inn imapextide) primary completion](https://sec-api.dev/pdufa/mbx-1416-inn-imapextide) | MBX | Postbariatric Hypoglycemia | completed | "NCT07029412 (Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-18 (ACTUAL); Lead Sponsor MBX Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07029412)) |
| October 2027 | [Mizagliflozin primary completion](https://sec-api.dev/pdufa/mizagliflozin) | VOGX | Postbariatric Hypoglycemia | scheduled | "NCT07760961 (Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Vogenx, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07760961)) |
| Oct 2027 to Jan 2028 | [Mizagliflozin topline data readout](https://sec-api.dev/pdufa/mizagliflozin) | VOGX | Postbariatric Hypoglycemia | scheduled | "NCT07760961 (Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Vogenx, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07760961)) |

## Drugs

- [Mbx 1416 (inn imapextide)](https://sec-api.dev/pdufa/mbx-1416-inn-imapextide) (MBX)
- [Mizagliflozin](https://sec-api.dev/pdufa/mizagliflozin) (VOGX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/postbariatric-hypoglycemia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Postbariatric Hypoglycemia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/postbariatric-hypoglycemia

```bibtex
@misc{secapidev_indications_postbariatric_hypoglycemia_20261116,
  title        = {Postbariatric Hypoglycemia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/postbariatric-hypoglycemia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_postbariatric_hypoglycemia_20261116","title":"Postbariatric Hypoglycemia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/postbariatric-hypoglycemia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
